Iberdomide plus daratumumab and dexamethasone versus daratumumab,…
Adding iberdomide to standard myeloma therapy improved sustained cancer remission rates, offering hope for patients whose disease had resisted prior treatments.
- Lab
- Preclinical
- Early trials
- Late trials
- In practice
A Risk Prediction Model Based on Combined CBC and CPD Parameters for…
A machine-learning model using routine blood tests may help doctors quickly identify high-risk non-Hodgkin lymphoma patients who need closer attention.
Promising but preliminaryApplication advances of habitat imaging based on CT or PET/CT
New imaging techniques could help doctors better understand tumor complexity, potentially guiding smarter treatment choices for individual patients.
Novel or significantly improved treatmentEfficacy of CAR-T-Cell-Based Immunotherapies in Patients With Glioma
CAR-T cell therapy shows early promise against aggressive brain tumors, though response rates remain modest and warrant continued investigation.
Promising but preliminaryManaging IBS-Like Symptoms in Quiescent Inflammatory Bowel Disease
Dietary approaches may help ease stubborn digestive symptoms in IBD patients whose inflammation is controlled, addressing a common unmet need.